Linked Life Data

7354130

Source:http://linkedlifedata.com/resource/pubmed/id/7354130

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1980-4-25
pubmed:abstractText
24,25-dihydroxycholecalciferol [24,25-(OH)(2)D(3)], once considered a relatively inert metabolite of vitamin D(3), has been recently recognized as a metabolically active product in some species. In previous studies, we have shown that infusion of 24,25(OH)(2)D(3) into the thyroid artery of normal dogs results in prompt and complete suppression of parathyroid hormone (PTH) secretion. In this study, we have examined the metabolic consequences of oral administration of this metabolite in dogs with experimentally induced renal hyperparathyroidism. Dogs with comparable degrees of renal insufficiency (glomerular filtration rate, 10-15 ml/min) were treated for 3 wk with daily doses of either 2 mug of 24,25(OH)(2)D(3) or 50% ethanol, the vehicle in which the metabolite was suspended. After a 6-wk recovery period, treatments were reversed: dogs who had previously served as controls received the metabolite while dogs previously treated with metabolite received the vehicle. Administration of 24,25(OH)(2)D(3) resulted in a 40-60% decrease of immunoreactive PTH. This was associated with a small (0.1-0.2 mg/dl) but unequivocal decrease of serum ionized calcium. Calcium balance, which was slightly negative under control conditions, became slightly but definitively positive on treatment with 24,25(OH)(2)D(3). All other parameters measured, including total serum calcium, magnesium, phosphorus, creatinine, electrolytes, phosphorus excretion, and phosphorus balance, remained unchanged. The data support the hypothesis that 24,25(OH)(2)D(3) not only decreases PTH secretion but also functions as an anabolic hormone in bone under the conditions of this experiment.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-166093, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-183601, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-333287, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-337145, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-4342432, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-4346008, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-4719672, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-5057601, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-5699718, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-5780197, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-659599, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-874095, http://linkedlifedata.com/resource/pubmed/commentcorrection/7354130-953799
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
571-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
Metabolic consequences of oral administration of 24,25-dihydroxycholecalciferol to uremic dogs.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.